Zacks Research Issues Positive Forecast for Maximus Earnings

Maximus, Inc. (NYSE:MMS) – Equities researchers at Zacks Research increased their Q3 2026 earnings estimates for Maximus in a note issued to investors on Thursday, February 26th. Zacks Research analyst Team now anticipates that the health services provider will post earnings per share of $2.20 for the quarter, up from their prior estimate of $2.15. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Maximus’ current full-year earnings is $6.15 per share. Zacks Research also issued estimates for Maximus’ Q4 2026 earnings at $2.28 EPS, FY2026 earnings at $8.34 EPS, Q3 2027 earnings at $2.37 EPS, Q4 2027 earnings at $1.90 EPS, Q1 2028 earnings at $2.00 EPS and FY2028 earnings at $8.94 EPS.

Maximus (NYSE:MMS) last released its quarterly earnings data on Thursday, February 5th. The health services provider reported $1.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.84 by $0.01. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.37 billion. Maximus had a net margin of 6.92% and a return on equity of 25.30%. Maximus’s revenue for the quarter was down 4.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.61 earnings per share. Maximus has set its FY 2026 guidance at 8.050-8.350 EPS.

A number of other equities research analysts have also recently commented on the stock. Weiss Ratings cut shares of Maximus from a “buy (b)” rating to a “hold (c+)” rating in a report on Tuesday, February 24th. Wall Street Zen downgraded Maximus from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy”.

Maximus Stock Down 0.2%

Shares of NYSE:MMS opened at $75.52 on Monday. Maximus has a 1-year low of $63.77 and a 1-year high of $100.00. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.34 and a quick ratio of 2.34. The stock has a market cap of $4.12 billion, a P/E ratio of 11.49 and a beta of 0.59. The firm has a fifty day moving average price of $86.80 and a 200 day moving average price of $86.39.

Maximus Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 2nd. Shareholders of record on Friday, February 13th will be given a dividend of $0.33 per share. This represents a $1.32 annualized dividend and a yield of 1.7%. The ex-dividend date is Friday, February 13th. This is a positive change from Maximus’s previous quarterly dividend of $0.30. Maximus’s payout ratio is presently 20.09%.

Insider Transactions at Maximus

In other Maximus news, CFO David Mutryn purchased 1,000 shares of Maximus stock in a transaction dated Monday, February 9th. The stock was acquired at an average cost of $75.62 per share, with a total value of $75,620.00. Following the acquisition, the chief financial officer directly owned 40,037 shares of the company’s stock, valued at $3,027,597.94. This represents a 2.56% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Michelle F. Link sold 4,039 shares of the stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $86.84, for a total value of $350,746.76. Following the completion of the transaction, the insider owned 19,542 shares of the company’s stock, valued at $1,697,027.28. The trade was a 17.13% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 1.80% of the company’s stock.

Institutional Trading of Maximus

Institutional investors have recently added to or reduced their stakes in the stock. Savant Capital LLC raised its stake in Maximus by 84.1% during the second quarter. Savant Capital LLC now owns 10,055 shares of the health services provider’s stock worth $706,000 after purchasing an additional 4,594 shares during the period. Magnetar Financial LLC raised its position in shares of Maximus by 123.5% in the 2nd quarter. Magnetar Financial LLC now owns 12,774 shares of the health services provider’s stock worth $897,000 after buying an additional 7,059 shares during the period. Deprince Race & Zollo Inc. raised its position in shares of Maximus by 147.1% in the 3rd quarter. Deprince Race & Zollo Inc. now owns 243,695 shares of the health services provider’s stock worth $22,266,000 after buying an additional 145,062 shares during the period. Bank of New York Mellon Corp boosted its holdings in Maximus by 1.6% in the second quarter. Bank of New York Mellon Corp now owns 549,369 shares of the health services provider’s stock valued at $38,566,000 after acquiring an additional 8,434 shares during the last quarter. Finally, Boston Partners grew its position in Maximus by 113.6% during the second quarter. Boston Partners now owns 657,247 shares of the health services provider’s stock valued at $46,435,000 after acquiring an additional 349,529 shares during the period. Hedge funds and other institutional investors own 97.21% of the company’s stock.

Maximus Company Profile

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.